The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing
oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions …

Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor
progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong …

Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple
biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in …

PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation
through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell…

The majority of lung cancer patients progressing from conventional therapies are refractory
to PD ‐L1/ PD ‐1 blockade monotherapy. Here, we show that baseline systemic CD 4 …

Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (…

PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1
blockade anticancer therapies, particularly for lung cancer. However, the reliability of this …

PD-L1/PD-1 blockade immunotherapy has significantly improved treatment outcome for
several cancer types compared to conventional cytotoxic therapies. However, the specific …

Hyperprogressive disease (HPD) is an adverse outcome of immunotherapy consisting of an
acceleration of tumor growth associated with prompt clinical deterioration. The definitions …

Cancer immunotherapies targeting immune checkpoints such as programmed cell-death
protein 1 (PD-1) and its ligand programmed cell-death 1 ligand 1 (PD-L1), are revolutionizing …